Why the study?
Discriminating between non-ST-elevation ACS and acute heart failure is challenging due to overlapping symptoms, particularly in patients with equivocal clinical presentations.
Do copeptin and hs-cTnT levels discriminate acute heart failure from uncomplicated NSTE-ACS in patients with elevated baseline hs-cTnT?
Do copeptin and hs-cTnT levels discriminate acute heart failure from uncomplicated NSTE-ACS in patients with elevated baseline hs-cTnT?
Copeptin provides better discrimination than hs-cTnT for distinguishing acute heart failure from uncomplicated NSTE-ACS in patients with equivocal presentations and elevated baseline troponin.
Answers are grounded in this paper and cite their sources.
Copeptin may aid differentiation of acute HF from NSTE-ACS in elevated-troponin patients; leaves open prospective validation before clinical adoption.
BACKGROUND: In light of overlapping symptoms, discrimination between non-ST-elevation (NSTE) acute coronary syndrome (ACS) and acute heart failure (HF) is challenging, particularly in patients with equivocal clinical presentation for suspected ACS. We sought to evaluate the diagnostic and prognostic properties of copeptin in this scenario. METHODS: Data from 1088 patients from a single-center observational registry were used to test the ability of serial high sensitivity cardiac troponin T (hs-cTnT)-compared to copeptin, or a combination of copeptin with hs-cTnT-to discriminate acute HF from uncomplicated non-ST-elevation myocardial infarction (NSTEMI) and to evaluate all-cause mortality after 365 days. Patients with STEMI, those with unstable angina and either normal or undetectable hs-cTnT concentrations were excluded. The findings were validated in an independent external NSTE-ACS cohort. In the test cohort, the area under the receiver operator curve (AUC) for the discrimination of acute HF vs. NSTE-ACS without HF was 0.725 (95% confidence interval [CI] 0.625-0.798) for copeptin and significantly higher than for hs-cTnT at 0 h (AUC = 0.460, 0.370-0.550) or at 3 h (AUC = 0.441, 0.343-0.538). Copeptin and hs-cTnT used either as continuous values or at cutoffs optimized to yield 90% specificity for acute HF were associated with significantly higher age- and sex-adjusted risk for all-cause mortality at 365 days. The findings from the test cohort were consistently replicated in the independent external NSTE-ACS validation cohort. CONCLUSIONS: High concentrations of copeptin in patients with suspected NSTE-ACS and equivocal clinical presentation suggest the presence of acute HF compared to uncomplicated NSTE-ACS and are associated with higher rates of all-cause death at 365 days.
No takes yet. Share an insight, caveat, or question.
Haehling et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: